crnx-8k_20190621.htm

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 21, 2019

 

Crinetics Pharmaceuticals, Inc.

(Exact name of registrant as specified in its charter)

 

 

 

 

 

 

 

Delaware

  

001-38583

  

26-3744114

(State or Other Jurisdiction of

Incorporation or Organization)

  

(Commission File Number)

  

(I.R.S. Employer Identification Number)

 

10222 Barnes Canyon Road, Bldg. #2

San Diego, California 92121

(Address of principal executive offices) (Zip Code)

(858) 450-6464

(Registrant’s telephone number, include area code)

N/A

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading

Symbol(s)

 

Name of each exchange on which registered

Common Stock, par value $0.001 per share

 

CRNX

 

Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company  

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  

 

 

 

 


 

Item 5.07

Submission of Matters to a Vote of Security Holders.

Crinetics Pharmaceuticals, Inc. (the “Company”) held its annual meeting of stockholders on June 21, 2019. The following is a brief description of each matter voted upon at the meeting and the number of votes cast for, withheld or against, the number of abstentions and the number of broker non-votes with respect to each matter, as applicable.

 

1.

The election of two directors to serve as Class I directors for a three-year term to expire at the 2022 annual meeting of stockholders. The following two Class I directors were re-elected by the votes indicated:

 

 

 

For

 

Withheld

 

Broker Non-Votes

R. Scott Struthers, Ph.D.

 

 

20,974,056

 

 

 

1,222,596

 

 

 

1,005,158

 

Matthew K. Fust

 

 

20,784,702

 

 

 

1,411,950

 

 

 

1,005,158

 

 

 

2.

The ratification of the selection of BDO USA, LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2019. The selection was ratified by the votes indicated:

 

For

 

Against

 

Abstain

 

Broker Non-Votes

 

23,199,209

 

 

 

0

 

 

 

2,601

 

 

 

0

 

 

1


 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

 

 

 

 

 

 

 

 

 

Crinetics Pharmaceuticals, Inc.

 

 

 

 

Date: June 25, 2019

 

 

 

 By:

 

/s/ R. Scott Struthers, Ph.D.

 

 

 

 

 

 

R. Scott Struthers, Ph.D.

 

 

 

 

 

 

President and Chief Executive Officer

 

2